Skip to main
KOD

KOD Stock Forecast & Price Target

KOD Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 29%
Hold 29%
Sell 0%
Strong Sell 0%

Bulls say

Kodiak Sciences Inc demonstrated a notable increase in its stock value during the third quarter, as the company advanced through four active Phase 3 trials with three lead assets, indicating strong progress in their pipeline and multiple anticipated data readouts through 2026. Research and development expenses rose significantly to $50.5 million, driven primarily by clinical and manufacturing costs, reflecting the company's commitment to furthering its innovative therapies. Encouraging follow-up data from the APEX study revealed continued improvement in best-corrected visual acuity (BCVA) for patients treated with KSI-101, adding to the positive outlook for Kodiak's product candidates and their potential market impact.

Bears say

Kodiak Sciences Inc faces significant challenges that contribute to a negative outlook on its stock, including the developmental candidates' potential failure to meet peak commercial revenue estimates due to market limitations and pricing issues. Additionally, the company has reported substantial financial losses, such as a net loss of $61.5 million in the third quarter of 2025, which raises concerns about its ability to secure the necessary capital for ongoing operations and commercialization efforts. Furthermore, the inconsistent efficacy of tarcocimab in clinical trials poses serious risks to the viability of its product pipeline and the overall success of its therapeutic platform.

KOD has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 29% recommend Buy, 29% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Kodiak Sciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Kodiak Sciences Inc (KOD) Forecast

Analysts have given KOD a Buy based on their latest research and market trends.

According to 7 analysts, KOD has a Buy consensus rating as of Jan 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $26.57, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $26.57, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Kodiak Sciences Inc (KOD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.